PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Adalimumab - Localised Psoriasis
PAD Profile : Adalimumab - Localised Psoriasis
Keywords :
Biologic, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Dermatology, biosimilar, high impact sites, PGA, Physicians Global Assessment
Brand Names Include :
Humira, Hyrimoz, Imraldi, Amgevita, Hulio, Yuflyma, Idacio
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
- Ankylosing spondylitis
- Inflammatory bowel disease
- Psoriasis
- Psoriasis (Hand and foot)
- Psoriatic arthritis
- Rheumatoid arthritis
- Non-radiographic axial spondyloarthritis
- Behcet's syndrome
- Non-infectious uveitis
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 July 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree the following immunomodulators for use in localised psoriasis
- Etanercept
- Infliximab
- Adalimumab
- Ustekinumab
- Secukinumab
- Ixekizumab
- Certolizumab
- Guselkumab
For use in the following body areas
• Head and neck – includes face and scalp
• Nails
• Genitals
• Hands and feet
• Flexures
These are all RED drugs, and the Dermatology teams will complete Blueteq forms for initiation and continuation.
Associated BNF Codes
13. Skin
13.05.03. Drugs affecting the immune response